ADAM17、EGFR 与 Ki-67 在恶性脑胶质瘤中的表达及相关性。

The correlation between the expression of ADAM17, EGFR and Ki-67 in malignant gliomas.

机构信息

Departments of Neurosurgery, Chinese People's Armed Police Force General Hospital, Beijing, China.

出版信息

Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4595-4599.

Abstract

OBJECTIVE

The aim of this study was to analyze the depolymerization in metalloproteinase (ADAM17), epidermal growth factor receptor (EGFR), the expression of Ki-67 of glioma patients and the correlations with malignancy.

PATIENTS AND METHODS

53 brain glioma samples resected from patients who had surgery from April 2015 to May 2016 at Chinese People's Armed Police Force General Hospital were selected. According to the degree of malignancy: 22 patients were divided into a deterioration group (stage I to II); 31 patients in highly deteriorated group (stage III to IV); 14 brain tissue samples of traumatic decompression from the hospital as control group. The immunohistochemical method was used to detect the expression of ADAM17, EGFR, and Ki-67 in three groups, and the correlation between the expression of ADAM17, EGFR, and Ki-67. Thus, the stages of malignancy were analyzed.

RESULTS

ADAM17, EGFR, and Ki-67 had no expression or weak expression in the control group, and increased in the low stage of deterioration group; the differences were statistically significant (p < 0.05). The positive expression rates of ADAM17, EGFR, and KI-67 were significantly higher in the high deterioration group than that in the control group (p < 0.05). Moreover, the analysis showed that the expression of ADAM17, EGFR, and Ki-67 were positively correlated with the stage of malignancy (R = 0.823, p = 0.000; R = 0.804, p = 0.000; R = 0.811, p = 0.000).

CONCLUSIONS

The results suggested that there was a significant positive correlation between ADAM17, EGFR, and Ki-67 with the stage of malignancy.

摘要

目的

本研究旨在分析神经胶母细胞瘤患者中解聚素金属蛋白酶 17（ADAM17）、表皮生长因子受体（EGFR）、Ki-67 的表达及其与恶性程度的相关性。

方法

选取 2015 年 4 月至 2016 年 5 月武警总医院神经外科手术切除的脑胶质瘤标本 53 例，根据恶性程度分为进展组（Ⅰ~~Ⅱ级）22 例、高度进展组（Ⅲ~~Ⅳ级）31 例，另取同期因颅脑外伤行减压术的 14 例患者的脑组织标本作为对照组。采用免疫组化法检测三组 ADAM17、EGFR、Ki-67 的表达，并分析 ADAM17、EGFR、Ki-67 表达与恶性程度的相关性。

结果

对照组 ADAM17、EGFR、Ki-67 无表达或弱表达，在低进展组表达增强，差异均有统计学意义（p＜0.05）；高度进展组 ADAM17、EGFR、Ki-67 阳性表达率明显高于对照组，差异均有统计学意义（p＜0.05）。相关性分析显示，ADAM17、EGFR、Ki-67 表达与肿瘤恶性程度呈正相关（R=0.823，p=0.000；R=0.804，p=0.000；R=0.811，p=0.000）。